105 Paseo de Roxas St.
Tel: (+632) 982 3500
Current position: Partner
Practice area/industry focus: Mergers and Acquisitions, Competition & Antitrust, Technology Media & Telecommunications
Career highlights: Mr. Larcina advises on various aspects of Philippine competition law, including merger control,vertical restrictions, and development of antitrust compliance programs.
In the area of merger control, his work highlights include acting as Philippine anti-trust counsel of Sanofi in its acquisition of Boehringer Ingelheim's consumer healthcare business (resulting in the first merger clearance to be issued by the Philippine Competition Commission after a full review), Alipay of the Ant Financial Group in its investment in the fintech enterprise of Globe Telecoms (where the PCC conducted its first Phase II review and which was unconditionally approved), Japan Tobacco in its acquisition of the assets of Mighty Corporation (one of the largest local M&A transactions in 2017), Grab in its acquisition of Uber's Southeast Asian Assets (the first transaction to be reviewed by the PCC motu proprio) and GlaxoSmithKline in its acquisition of Pfizer's consumer healthcare business (also subjected to a Phase II review and unconditionally approved).
He also regularly advises clients on structures that do not trigger Philippine compulsory merger notification and has assisted in securing confirmation of non-coverage from the PCC. Mr. Larcina has been included in Who's Who Legal: Competition Future Leaders for the years 2017, 2018 and 2019.
Asialaw Distinguished Practitioner 2020 in Competition/antitrust